Phospholipase D1 is an effector of Rheb in the mTOR pathway

Y. Sun, Y. Fang, M. S. Yoon, C. Zhang, M. Roccio, F. J. Zwartkruis, M. Armstrong, H. A. Brown, J. Chen

Research output: Contribution to journalArticle

Abstract

The mammalian target of rapamycin (mTOR) assembles a signaling network essential for the regulation of cell growth, which has emerged as a major target of anticancer therapies. The tuberous sclerosis complex 1 and 2 (TSC1/2) proteins and their target, the small GTPase Rheb, constitute a key regulatory pathway upstream of mTOR. Phospholipase D (PLD) and its product phosphatidic acid are also upstream regulators of the mitogenic mTOR signaling. However, how the TSC/Rheb and PLD pathways interact or integrate in the rapamycin-sensitive signaling network has not been examined before. Here, we find that PLD1, but not PLD2, is required for Rheb activation of the mTOR pathway, as demonstrated by the effects of RNAi. The overexpression of Rheb activates PLD1 in cells in the absence of mitogenic stimulation, and the knockdown of Rheb impairs serum stimulation of PLD activation. Furthermore, the overexpression of TSC2 suppresses PLD1 activation, whereas the knockdown or deletion of TSC2 leads to elevated basal activity of PLD. Consistent with a TSC-Rheb-PLD signaling cascade, AMPK and PI3K, both established regulators of TSC2, appear to lie upstream of PLD as revealed by the effects of pharmacological inhibitors, and serum activation of PLD is also dependent on amino acid sufficiency. Finally, Rheb binds and activates PLD1 in vitro in a GTP-dependent manner, strongly suggesting that PLD1 is a bona fide effector for Rheb. Hence, our findings reveal an unexpected interaction between two cascades in the mTOR signaling pathways and open up additional possibilities for targeting this important growth-regulating network for the development of anticancer drugs.

Original languageEnglish (US)
Pages (from-to)8286-8291
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume105
Issue number24
DOIs
StatePublished - Jun 17 2008

Fingerprint

Phospholipase D
Sirolimus
Phosphatidic Acids
AMP-Activated Protein Kinases
Monomeric GTP-Binding Proteins
Growth
RNA Interference
Guanosine Triphosphate
phospholipase D1
Serum
Phosphatidylinositol 3-Kinases
Pharmacology
Amino Acids
Pharmaceutical Preparations

Keywords

  • Phosphatidic acid
  • Rapamycin
  • Tuberous sclerosis complex

ASJC Scopus subject areas

  • General

Cite this

Phospholipase D1 is an effector of Rheb in the mTOR pathway. / Sun, Y.; Fang, Y.; Yoon, M. S.; Zhang, C.; Roccio, M.; Zwartkruis, F. J.; Armstrong, M.; Brown, H. A.; Chen, J.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 105, No. 24, 17.06.2008, p. 8286-8291.

Research output: Contribution to journalArticle

Sun, Y, Fang, Y, Yoon, MS, Zhang, C, Roccio, M, Zwartkruis, FJ, Armstrong, M, Brown, HA & Chen, J 2008, 'Phospholipase D1 is an effector of Rheb in the mTOR pathway', Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 24, pp. 8286-8291. https://doi.org/10.1073/pnas.0712268105
Sun, Y. ; Fang, Y. ; Yoon, M. S. ; Zhang, C. ; Roccio, M. ; Zwartkruis, F. J. ; Armstrong, M. ; Brown, H. A. ; Chen, J. / Phospholipase D1 is an effector of Rheb in the mTOR pathway. In: Proceedings of the National Academy of Sciences of the United States of America. 2008 ; Vol. 105, No. 24. pp. 8286-8291.
@article{c2c192a52c304ffd91d5a2df55dcd962,
title = "Phospholipase D1 is an effector of Rheb in the mTOR pathway",
abstract = "The mammalian target of rapamycin (mTOR) assembles a signaling network essential for the regulation of cell growth, which has emerged as a major target of anticancer therapies. The tuberous sclerosis complex 1 and 2 (TSC1/2) proteins and their target, the small GTPase Rheb, constitute a key regulatory pathway upstream of mTOR. Phospholipase D (PLD) and its product phosphatidic acid are also upstream regulators of the mitogenic mTOR signaling. However, how the TSC/Rheb and PLD pathways interact or integrate in the rapamycin-sensitive signaling network has not been examined before. Here, we find that PLD1, but not PLD2, is required for Rheb activation of the mTOR pathway, as demonstrated by the effects of RNAi. The overexpression of Rheb activates PLD1 in cells in the absence of mitogenic stimulation, and the knockdown of Rheb impairs serum stimulation of PLD activation. Furthermore, the overexpression of TSC2 suppresses PLD1 activation, whereas the knockdown or deletion of TSC2 leads to elevated basal activity of PLD. Consistent with a TSC-Rheb-PLD signaling cascade, AMPK and PI3K, both established regulators of TSC2, appear to lie upstream of PLD as revealed by the effects of pharmacological inhibitors, and serum activation of PLD is also dependent on amino acid sufficiency. Finally, Rheb binds and activates PLD1 in vitro in a GTP-dependent manner, strongly suggesting that PLD1 is a bona fide effector for Rheb. Hence, our findings reveal an unexpected interaction between two cascades in the mTOR signaling pathways and open up additional possibilities for targeting this important growth-regulating network for the development of anticancer drugs.",
keywords = "Phosphatidic acid, Rapamycin, Tuberous sclerosis complex",
author = "Y. Sun and Y. Fang and Yoon, {M. S.} and C. Zhang and M. Roccio and Zwartkruis, {F. J.} and M. Armstrong and Brown, {H. A.} and J. Chen",
year = "2008",
month = "6",
day = "17",
doi = "10.1073/pnas.0712268105",
language = "English (US)",
volume = "105",
pages = "8286--8291",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
publisher = "National Academy of Sciences",
number = "24",

}

TY - JOUR

T1 - Phospholipase D1 is an effector of Rheb in the mTOR pathway

AU - Sun, Y.

AU - Fang, Y.

AU - Yoon, M. S.

AU - Zhang, C.

AU - Roccio, M.

AU - Zwartkruis, F. J.

AU - Armstrong, M.

AU - Brown, H. A.

AU - Chen, J.

PY - 2008/6/17

Y1 - 2008/6/17

N2 - The mammalian target of rapamycin (mTOR) assembles a signaling network essential for the regulation of cell growth, which has emerged as a major target of anticancer therapies. The tuberous sclerosis complex 1 and 2 (TSC1/2) proteins and their target, the small GTPase Rheb, constitute a key regulatory pathway upstream of mTOR. Phospholipase D (PLD) and its product phosphatidic acid are also upstream regulators of the mitogenic mTOR signaling. However, how the TSC/Rheb and PLD pathways interact or integrate in the rapamycin-sensitive signaling network has not been examined before. Here, we find that PLD1, but not PLD2, is required for Rheb activation of the mTOR pathway, as demonstrated by the effects of RNAi. The overexpression of Rheb activates PLD1 in cells in the absence of mitogenic stimulation, and the knockdown of Rheb impairs serum stimulation of PLD activation. Furthermore, the overexpression of TSC2 suppresses PLD1 activation, whereas the knockdown or deletion of TSC2 leads to elevated basal activity of PLD. Consistent with a TSC-Rheb-PLD signaling cascade, AMPK and PI3K, both established regulators of TSC2, appear to lie upstream of PLD as revealed by the effects of pharmacological inhibitors, and serum activation of PLD is also dependent on amino acid sufficiency. Finally, Rheb binds and activates PLD1 in vitro in a GTP-dependent manner, strongly suggesting that PLD1 is a bona fide effector for Rheb. Hence, our findings reveal an unexpected interaction between two cascades in the mTOR signaling pathways and open up additional possibilities for targeting this important growth-regulating network for the development of anticancer drugs.

AB - The mammalian target of rapamycin (mTOR) assembles a signaling network essential for the regulation of cell growth, which has emerged as a major target of anticancer therapies. The tuberous sclerosis complex 1 and 2 (TSC1/2) proteins and their target, the small GTPase Rheb, constitute a key regulatory pathway upstream of mTOR. Phospholipase D (PLD) and its product phosphatidic acid are also upstream regulators of the mitogenic mTOR signaling. However, how the TSC/Rheb and PLD pathways interact or integrate in the rapamycin-sensitive signaling network has not been examined before. Here, we find that PLD1, but not PLD2, is required for Rheb activation of the mTOR pathway, as demonstrated by the effects of RNAi. The overexpression of Rheb activates PLD1 in cells in the absence of mitogenic stimulation, and the knockdown of Rheb impairs serum stimulation of PLD activation. Furthermore, the overexpression of TSC2 suppresses PLD1 activation, whereas the knockdown or deletion of TSC2 leads to elevated basal activity of PLD. Consistent with a TSC-Rheb-PLD signaling cascade, AMPK and PI3K, both established regulators of TSC2, appear to lie upstream of PLD as revealed by the effects of pharmacological inhibitors, and serum activation of PLD is also dependent on amino acid sufficiency. Finally, Rheb binds and activates PLD1 in vitro in a GTP-dependent manner, strongly suggesting that PLD1 is a bona fide effector for Rheb. Hence, our findings reveal an unexpected interaction between two cascades in the mTOR signaling pathways and open up additional possibilities for targeting this important growth-regulating network for the development of anticancer drugs.

KW - Phosphatidic acid

KW - Rapamycin

KW - Tuberous sclerosis complex

UR - http://www.scopus.com/inward/record.url?scp=46149098447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46149098447&partnerID=8YFLogxK

U2 - 10.1073/pnas.0712268105

DO - 10.1073/pnas.0712268105

M3 - Article

C2 - 18550814

AN - SCOPUS:46149098447

VL - 105

SP - 8286

EP - 8291

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 24

ER -